Bevacizumab gamma for treating wet age-related macular degeneration

Final draft guidance

Final draft guidance (PDF 133 KB)

Committee papers (PDF 4.1 MB)

Equality impact assessment (downloadable version) (PDF 121 KB)

Final scope (PDF 187 KB)

Final stakeholder list (PDF 171 KB)

NICE's response to comments on the draft scope and provisional stakeholder list (PDF 349 KB)

Equality impact assessment (Scoping) (PDF 124 KB)

Draft matrix post referral (PDF 173 KB)

Draft scope post referral (PDF 201 KB)